《中国肺动脉高压诊断与治疗指南(2021版)》解读——结缔组织病相关肺动脉高压

Interpretation of the Guidelines to the diagnosis and treatment of pulmonary hypertension in China(2021):pulmonary hypertension associated with connective tissue disease

肺动脉高压(PH)是结缔组织病(CTD)的严重并发症之一,其中,以第一大类PH,即动脉性肺动脉高压(PAH)最为常见。因起病隐匿、临床表现缺乏特异性、早期诊断困难、治疗效果不佳,PAH已成为CTD患者死亡的重要因素之一。文章针对中华医学会呼吸病学分会肺栓塞与肺血管病学组发布的《中国肺动脉高压诊断与治疗指南(2021版)》中CTD相关PAH部分的推荐意见进行解读,提倡CTD相关PAH的早期筛查、精确诊断、全面评估和精准治疗,以期改善CTD相关PAH患者的长期预后,提高患者生活质量。

Pulmonary hypertension(PH)is one of the serious complications of connective tissue disease(CTD).Among them,the first type of PH,namely arterial pulmonary hypertension(PAH),is the most common.Due to the insidious onset,lack of specific clinical manifestations,difficulty in early diagnosis,and poor treatment effects,PAH has become one of the important factors in the death of CTD patients.This article interprets the recommendations of the CTD-related PAH section of the Guidelines to the diagnosis and treatment of pulmonary hypertension in China(2021)issued by the Pulmonary Embolism and Pulmonary Vascular Disease Group of the Respiratory Diseases Branch of the Chinese Medical Association,and promote early screening,accurate diagnosis,comprehensive evaluation and precise treatment of CTD-related PAH in order to improve the long-term prognosis of patients with CTD-related PAH and improve the quality of life of patients.